Glycemic Control Among Patients Newly Prescribed IDegLira Across Prior Therapy Group in US Real-World Practice

INTRODUCTION: IDegLira is a fixed-ratio combination of insulin degludec and liraglutide indicated for the treatment of type 2 diabetes (T2D). We report the first real-world study describing change in glycated hemoglobin (HbA1c) among US patients who initiated IDegLira. The aim of the study was to ob...

Descripción completa

Detalles Bibliográficos
Autores principales: Egede, Leonard E., Bogdanov, Alina, Fischer, Lauren, Da Rocha Fernandes, João Diogo, Kallenbach, Lee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7324461/
https://www.ncbi.nlm.nih.gov/pubmed/32506223
http://dx.doi.org/10.1007/s13300-020-00850-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7324461/
https://www.ncbi.nlm.nih.gov/pubmed/32506223
http://dx.doi.org/10.1007/s13300-020-00850-w

Ejemplares similares